Author

L. Espada

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:C. elegans· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

M. Ermolaeva· 2 shared T. Poliezhaieva· 2 shared A. Dakhovnik· 1 shared A. Koeberle· 1 shared A. Martirosyan· 1 shared A. Nair· 1 shared A. Ori· 1 shared C. Breunig· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

M. Ermolaeva

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Aging-associated decline of phosphatidylcholine synthesis is a malleable trigger of natural mitochondrial aging.

T. Poliezhaieva, P. A. Pernas, L. Espada, M. Bayar, Y. Li, H. M. Donertas, M. Ermolaeva

The paper identifies a decline in phosphatidylcholine synthesis as a driver of mitochondrial aging that can be reversed by dietary interventions in both worms and human cells.

bioRxiv · Apr 25, 2024Cell Biology

Nanobodies against SARS-CoV-2 non-structural protein Nsp9 inhibit viral replication by targeting innate immunity

T. Venit, J. Blavier, S. B. Maseko, S. Shu, L. Espada, C. Breunig, H.-P. Holthoff, S. C. Desbordes, M. Lohse, G. Esposito, J.-C. Twizere, P. Percipalle

This paper designs nanobodies against SARS-CoV-2 Nsp9 to inhibit viral replication, showing effectiveness against multiple variants in HEK293-ACE2 cells.

bioRxiv · Oct 12, 2023 · PreprintCell Biology

Late life metformin treatment limits cell survival and shortens lifespan by triggering an aging-associated failure of energy metabolism.

L. Espada, A. Dakhovnik, P. S. Chaudhari, A. Martirosyan, L. Miek, T. Poliezhaieva, Y. Schaub, A. Nair, N. Doering, N. Rahnis, O. Werz, A. Koeberle, J. Kirkpatrick, A. Ori, M. Ermolaeva

This study shows that late-life metformin treatment reduces cell survival and lifespan by impairing energy metabolism, contrasting its beneficial effects in early life.

bioRxiv · Dec 3, 2019 · PreprintPhysiology